OncoSec Medical Inc (ONCSQ)

[Titan V]

I was looking at this yesterday. Among their 7 anti-PD-1 naive patients that showed a 100% ORR, one cannot tell for sure if they responded as such due to the combo treatment or due to Keytruda alone, the same question that was raised for ONCS's responders in the IST. At least with ONCS, we had some measure that the patients were predicted non-responders to Keytruda alone.

As for the anti-PD1 refractory patients, the response rates are less than ONCS's - not a single complete response and a lower partial response rate of 17% compared to the 22% (2 out of 9 pts) of ONCS.

Still not conclusive as to which one is the better therapy due to the small samples, but the upcoming registration trial should provide a better picture.